Key result
The HAS-BLED score showed only modest predictive value for bleeding complications during the first three months of VTE treatment (AUC 0.68; 95% CI 0.59-0.78).
Why the study?
Do contemporary bleeding risk scores accurately predict bleeding complications in patients on long-term vitamin K antagonists for VTE?
Population
681 adult patients on vitamin K antagonists for VTE secondary prevention, median age 63 years, 52.0% female…
Design
Cohort
Follow-up
mean 8.82 (± 3.59) months
Authors
Loading...
Modest HAS-BLED performance advises against sole reliance for early VTE bleeding risk; leaves open need for VTE-specific scores.
Cohort (n=681)
Yes
Do contemporary bleeding risk scores accurately predict bleeding complications in patients on long-term vitamin K antagonists for VTE?
Effect estimate: AUC 0.68 (95% CI 0.59-0.78)
Currently available bleeding risk scores have only modest predictive value for VTE patients on long-term vitamin K antagonists, highlighting the need for VTE-specific prediction rules.
Bellesini et al. (2014) conducted a cohort in Venous thromboembolism (n=681). Bleeding risk scores (HAS-BLED and ACCP) was evaluated on Bleeding complications during the first three months of treatment (AUC 0.68, 95% CI 0.59-0.78). The HAS-BLED score showed only modest predictive value for bleeding complications during the first three months of VTE treatment (AUC 0.68; 95% CI 0.59-0.78).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: